Dr. Tuscano's areas of specialty include the treatment of leukemia, lymphoma, MDS, and multiple myeloma. He is also a member of the adult stem cell transplant team. He has both basic/translation and clinical research interests that include the development of novel antibody and other immune-based therapeutics for hematologic malignancies.

Title:

Professor

Specialty:

Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation:

Bone Marrow Transplant Program, UC Davis Comprehensive Cancer Center

Address:

UC Davis Comprehensive Cancer Center
4501 X St.
Sacramento, CA 95817

Phone:

916-734-5959

Education:

University of Southern California School of Medicine
Los Angeles, California
M.D. 1989

California State University, Sacramento
Sacramento, California
B.S. 1985

Internships:

University of California, Davis, Medical Center
Sacramento, California
1989-1992

Residency:

University of California, Davis, Medical Center
Sacramento, California
1989-1992
Internal Medicine

Fellowships:

UC Davis Medical Center
Sacramento, California
1997-1998
Bone Marrow Transplant Program

National Institutes of Health
Bethesda, Maryland
1994-1996
Oncology

National Institutes of Health
Bethesda, Maryland
1992-1994
Immunology

Board Certifications:

American Board of Internal Medicine, Medical Oncology, 1998

Professional Memberships:

American College of Physicians
American Medical Association
American Society of Clinical Oncology
American Society of Hematology

Honors and Awards:

Patent Pending: Fermented wheat germ proteins (FWGP) for the treatment of cancer. 05/20/2009, 2009
Pending Patent: Treatment methods using anti-CD22 antibodies. Date of US Patent Provisional Application - 02/13/02, 2002
University - Cure for Lymphoma Scholar Award, 1999
University - Christine Landgraf Memorial Award, 1997
Fellowship - NIH Fellows Award for Research Excellence, 1996
Fellowship - National Research Service Award, 1993-94
Medical School - Honors in Hematology, Endocrinology, Medicine, 1987-88
Undergraduate - Dean's Scholar, 1982-84

Select Recent Publications:

Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res, 16(10): 2760-8. 2010

Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J. Comparison of Multiplex Suspension Array Large-Panel Kits for Profiling Cytokines and Chemokines in Rheumatoid Arthritis Patients. Cytometry B Clin Cytom. 76(3):159-168. 2009

Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. Lenalidomide oral mono therapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 145(3):344-349. 2009

O'Donnell RT, Pearson D, McKnight HC, Ma YF, Tuscano JM. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 33(7):964-969. 2009

Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin lymphoma xenografts. Mol Imaging Biol. 11(2):79-87. 2009

O'Donnell RT, Martin SM, Ma YF, Zamboni WC, Tuscano JM. Development and characterization of CD22-targeted pegylatedliposomal doxorubicin (IL-PLD). Invest New Drugs. 2009 Mar 24. 2009 [Epub ahead of print]

O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother, 58(12): 2051-8. 2009

Tuscano JM, Sands J. B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics, 3: 225-32. 2009

Pearson D, O'Donnell RT, Cerejo M, McKnight HC, Wang X, Marik J, Lam KS, Tuscano JM. CD22-Binding Peptides Derived from Anti-CD22 Ligand Blocking Antibodies Retain the Targeting and Cell Killing Properties of the Parent Antibodies and May Serve as a Drug Delivery Vehicle. Int J Pept Res Ther. 14(3):237-246. 2008

Tuscano JM. Multiple myeloma: epidemiology and therapeutic options. Manag Care. 17(7 SuppI6):9-15. 2008

To see if Joseph M. Tuscano is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.